{"product_id":"buchang-pestle-analysis","title":"Buchang Pharmaceutical PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnderstand how regulatory shifts, economic trends, and rapid biopharma innovation are shaping Buchang Pharmaceutical’s risks and opportunities—our concise PESTLE highlights the most impactful external forces and what they mean for strategy and valuation; purchase the full PESTLE to get the complete, actionable breakdown for investors, consultants, or planners.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Support for TCM Modernization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUnder Healthy China 2030, Beijing earmarked over CNY 1.5 trillion for healthcare reform through 2025, reinforcing TCM integration; Buchang accesses provincial and national subsidies, with reported R\u0026amp;D grants exceeding CNY 120 million in 2024.\u003c\/p\u003e\n\u003cp\u003eFavorable policies—tax breaks, accelerated approvals and inclusion in national insurance lists—helped Buchang grow TCM cardiovascular\/cerebrovascular revenue by ~18% in 2024, stabilizing cash flows for pipeline expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Centralized Volume Based Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInclusion of TCM in China’s National Volume-Based Procurement (VBP) forces Buchang to accept price caps—average VBP cuts of 50–60% for selected drugs—trading margin for guaranteed scale; Buchang reported a 2024 TCM revenue lift of ~18% in VBP-covered SKUs but saw gross margins compressing by ~8 ppt on those lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reform and Accessibility Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOngoing Chinese healthcare reforms target greater affordability and access for chronic disease care in rural areas, with government plans to raise rural healthcare funding by about 10% in 2024–25 and expand reimbursement coverage to another 50–80 million people; Buchang, with leading antihypertensive and cerebrovascular drugs, is well positioned to gain volume growth. Political pressure to lower out-of-pocket costs is pushing inclusion in national insurance formularies—Buchang reported 2024 domestic revenue of RMB 3.2 billion, benefiting from broader coverage. Regulatory emphasis on primary care procurement and essential medicines lists could further boost Buchang’s market share in underserved regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Relations and Export Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs Buchang expands abroad, geopolitical tensions and divergent Western regulatory standards for herbal medicines complicate market entry; EU pharmacopoeia and FDA botanical guidance demand data often beyond Chinese TCM dossiers, increasing compliance costs—estimated regulatory and market-entry expenses can add 5–10% to project budgets.\u003c\/p\u003e\n\u003cp\u003eMonitoring trade agreements is critical: in 2024, China-EU trade tensions and U.S. tariff measures risk tariffs or import bans on certain TCM ingredients, potentially affecting \u0026gt;30% of Buchang’s exportable herbal inputs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory gaps: EU\/FDA vs Chinese TCM standards\u003c\/li\u003e\n\u003cli\u003eAdded compliance cost: ~5–10% of project budgets\u003c\/li\u003e\n\u003cli\u003eExport risk: \u0026gt;30% of herbal inputs exposed to tariffs\/import bans\u003c\/li\u003e\n\u003cli\u003eRequires political engagement and enhanced certification strategies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Oversight on Pharmaceutical Ethics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Chinese government stepped up anti-bribery enforcement, with inspections and fines rising over 40% in 2023-2024; Buchang, previously flagged for high sales and promotion expenses (marketing spend ~12% of revenue in 2023), faces heightened compliance risk and must align with evolving anti-corruption laws to protect licenses and reputation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2023 marketing spend ≈12% of revenue\u003c\/li\u003e\n\u003cli\u003eEnforcement actions up \u0026gt;40% (2023–2024)\u003c\/li\u003e\n\u003cli\u003eNoncompliance risks license revocation and reputational damage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuchang boosted by Healthy China support but margins, export risks bite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolicy support under Healthy China 2030 (CNY 1.5tn to 2025) and R\u0026amp;D grants \u0026gt;CNY 120m in 2024 boosted Buchang’s domestic revenue to RMB 3.2bn (2024) with TCM cardiovascular lines up ~18% while VBP price caps cut gross margins ~8 ppt on covered SKUs; export compliance and tariffs risk \u0026gt;30% of herbal inputs, adding ~5–10% to project costs amid \u0026gt;40% rise in anti‑bribery enforcement (2023–24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023–24\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 3.2bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D grants\u003c\/td\u003e\n\u003ctd\u003eCNY \u0026gt;120m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTCM revenue growth\u003c\/td\u003e\n\u003ctd\u003e~18% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVBP margin impact\u003c\/td\u003e\n\u003ctd\u003e−8 ppt on covered SKUs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\/entry cost\u003c\/td\u003e\n\u003ctd\u003e+5–10% project budgets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHerbal input export risk\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30% exposed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnti‑bribery enforcement\u003c\/td\u003e\n\u003ctd\u003e+40% (2023–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Buchang Pharmaceutical across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-driven trends and region-specific regulatory context to identify risks and opportunities for executives and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise PESTLE summary of Buchang Pharmaceutical highlighting regulatory, economic, and technological risks and opportunities, formatted for quick insertion into presentations or strategy sessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of China's GDP Growth Stabilization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChina's GDP growth stabilized at about 5.2% in 2024 and is projected near 4.8–5.2% for 2025, supporting government and private healthcare spending that reached roughly RMB 9.5 trillion in 2024; this underpins Buchang's market capacity for cardiovascular products.\u003c\/p\u003e\n\u003cp\u003eAs policy shifts toward high-quality growth and aging-care priorities, healthcare proved defensive—healthcare sector revenue grew ~7% in 2024—attracting steady investment relevant to Buchang's R\u0026amp;D and production plans.\u003c\/p\u003e\n\u003cp\u003eBuchang depends on this steady macro backdrop to sustain demand for its specialized cardiovascular treatments, with China's cardiovascular drug market estimated at ~RMB 160 billion in 2024, providing a stable addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising Healthcare Expenditure and Insurance Coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising national healthcare spending—China’s health expenditure reached about CNY 9.7 trillion in 2024, up ~6% YoY—and expansion of the Basic Medical Insurance fund bolster demand for Buchang’s TCM products.\u003c\/p\u003e\n\u003cp\u003eRecent additions of multiple TCM items to the 2023–2025 National Reimbursement Drug List cut out‑of‑pocket costs, lifting prescription volumes; TCM reimbursement penetration rose to roughly 22% of outpatient drug spend in 2024.\u003c\/p\u003e\n\u003cp\u003eThis policy-driven reimbursement growth creates a more predictable revenue base for Buchang, supporting stable cash flows for core product lines and aiding forecastability for FY2025 planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost Inflation in Raw Material Sourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe rising cost of natural herbal ingredients—up 12–18% in China’s medicinal plant sector in 2024 due to droughts and labor shortages—raises production costs for Buchang, as TCM depends on specific plant and animal derivatives; agricultural price volatility pushed raw-material input CPI for pharmaceuticals 9% y\/y in 2024. Buchang must use advanced procurement, long-term contracts and supplier diversification to hedge these inflationary pressures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic shifts toward innovation-driven industries have unlocked greater capital for pharmaceutical R\u0026amp;D in China, with national biotech funding reaching about RMB 450 billion in 2024; Buchang must allocate substantial revenue—historically ~12–15% of sales—to R\u0026amp;D to stay competitive versus TCM peers and Western multinationals.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D ROI for Buchang is realized through patented, high-margin launches: a single innovative drug approval can boost gross margins by 6–10 percentage points and add hundreds of millions RMB in annual revenue, aligning with industry benchmarks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuchang R\u0026amp;D spend ~12–15% of revenue (2023–24)\u003c\/li\u003e\n\u003cli\u003eChina biotech funding ~RMB 450 billion (2024)\u003c\/li\u003e\n\u003cli\u003eInnovative drug launch can raise gross margin ~6–10 ppt\u003c\/li\u003e\n\u003cli\u003eSuccessful product may add hundreds of millions RMB yearly\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Fluctuations and International Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs Buchang expands abroad, RMB fell about 5.7% vs USD and 7.1% vs EUR in 2023–2025 real effective terms, reducing price competitiveness for imports and affecting margins on exported TCM goods.\u003c\/p\u003e\n\u003cp\u003eCurrency swings raised imported lab equipment costs by an estimated 3–6% in 2024, pressuring capex; FX hedging and invoicing in USD\/EUR are becoming essential as overseas sales grew to ~18% of revenue in 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRMB volatility: −5.7% vs USD (2023–25)\u003c\/li\u003e\n\u003cli\u003eImported equipment cost impact: +3–6% (2024)\u003c\/li\u003e\n\u003cli\u003eExports\/pricing sensitivity as exports ≈18% of revenue (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina 2024: 5.2% GDP, CNY9.7T health spend, cardio CNY160B, R\u0026amp;D 12–15%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChina GDP ~5.2% (2024), health spending CNY 9.7T (2024), cardiovascular market ~CNY 160B (2024); biotech funding CNY 450B (2024); Buchang R\u0026amp;D 12–15% sales; herbal input prices +12–18% (2024); RMB −5.7% vs USD (2023–25); exports ~18% revenue (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024\/25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGDP growth\u003c\/td\u003e\n\u003ctd\u003e~5.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth spending\u003c\/td\u003e\n\u003ctd\u003eCNY 9.7T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardio market\u003c\/td\u003e\n\u003ctd\u003eCNY 160B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech funding\u003c\/td\u003e\n\u003ctd\u003eCNY 450B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e12–15% sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHerbal prices\u003c\/td\u003e\n\u003ctd\u003e+12–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMB vs USD\u003c\/td\u003e\n\u003ctd\u003e−5.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports\u003c\/td\u003e\n\u003ctd\u003e~18% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eBuchang Pharmaceutical PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe Buchang Pharmaceutical PESTLE Analysis preview shown here is the exact document you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751978578297,"sku":"buchang-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/buchang-pestle-analysis.png?v=1772236666","url":"https:\/\/matrixbcg.com\/products\/buchang-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}